CBLI: AI-Bewertung 50/100 — AI-Analyse (Apr 2026)
Cytocom, Inc. is a biopharmaceutical company focused on developing immunotherapies and radiation countermeasures. Their platform leverages Toll-like immune receptor activators to address unmet medical needs.
Unternehmensueberblick
Kurzfassung:
Was macht CBLI?
Was ist die Investmentthese fuer CBLI?
In welcher Branche ist CBLI taetig?
Welche Wachstumschancen hat CBLI?
- Entolimod for Radiation Countermeasure: Cytocom is developing Entolimod as a radiation countermeasure, targeting a market driven by government stockpiling and biodefense initiatives. The market size is projected to reach billions of dollars, driven by increasing global security concerns. Securing a government contract for Entolimod could provide a significant revenue stream and validate the company's technology. Timeline for potential approval and commercialization is estimated within the next 3-5 years, pending successful clinical trials.
- Entolimod for Oncology: Entolimod is also being investigated as an immunotherapy for various oncology indications. The immuno-oncology market is experiencing rapid growth, with a global market size projected to reach hundreds of billions of dollars by 2030. Positive clinical trial results in specific cancer types could lead to accelerated approval pathways and significant market penetration. Competition in this space is intense, requiring Cytocom to demonstrate superior efficacy and safety profiles.
- CBLB612 Development: CBLB612, a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor, represents a potential growth opportunity for Cytocom. Further development and clinical trials could unlock its therapeutic potential in various inflammatory and autoimmune diseases. The market for TLR2/TLR6 agonists is growing, driven by increasing understanding of the role of innate immunity in disease pathogenesis. The timeline for commercialization depends on successful preclinical and clinical studies.
- Mobilan for Immunotherapy: Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It represents another growth opportunity for Cytocom in the immunotherapy space. Development of Mobilan as a novel cancer therapy could attract partnerships and funding. The market for adenoviral-based therapies is expanding, driven by advancements in gene therapy and vaccine development. The timeline for commercialization depends on successful preclinical and clinical studies.
- CBL0137 for Cancer Treatment: CBL0137, a small molecule with a multi-targeted mechanism of action, holds promise for treating various types of cancer. Further research and clinical trials could lead to its development as a novel cancer therapy. The market for small molecule cancer drugs remains significant, despite the rise of biologics. The timeline for commercialization depends on successful preclinical and clinical studies.
- Market capitalization of $0.23 billion reflects investor valuation of Cytocom's pipeline and technology platform as of March 15, 2026.
- Negative P/E ratio of -16.38 indicates that Cytocom is currently not profitable, typical for biotechnology companies in the development stage.
- Gross margin of 100.0% suggests high potential profitability for approved products, but this is contingent on successful commercialization.
- Profit margin of -912.2% highlights the significant expenses associated with research and development in the biopharmaceutical industry.
- Beta of 0.68 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.
Welche Produkte und Dienstleistungen bietet CBLI an?
- Develops drugs that activate the immune system.
- Focuses on Toll-like immune receptor activators.
- Creates radiation countermeasures.
- Develops immunotherapies for oncology.
- Researches and develops CBLB612.
- Researches and develops Mobilan.
- Researches and develops CBL0137.
Wie verdient CBLI Geld?
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical trials.
- Seeks regulatory approval from agencies like the FDA.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through government contracts, licensing agreements, and product sales (if approved).
- Government agencies (for radiation countermeasures).
- Hospitals and oncology centers (for cancer therapies).
- Patients with cancer and radiation exposure risks.
- Pharmaceutical companies (through licensing agreements).
- Proprietary Toll-like receptor technology platform.
- Patent protection for drug candidates.
- Expertise in radiation countermeasure development.
- Established relationships with government agencies (potential).
Was koennte die CBLI-Aktie steigen lassen?
- Upcoming: Clinical trial results for Entolimod in radiation mitigation.
- Upcoming: Clinical trial results for Entolimod in oncology indications.
- Upcoming: Potential government contracts for radiation countermeasures.
- Ongoing: Advancements in Toll-like receptor technology platform.
- Ongoing: Strategic partnerships with pharmaceutical companies.
Was sind die wichtigsten Risiken fuer CBLI?
- Potential: Clinical trial failures for Entolimod.
- Potential: Regulatory setbacks and delays.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Inability to secure additional funding.
- Potential: Intellectual property challenges.
Was sind die wichtigsten Staerken von CBLI?
- Proprietary Toll-like receptor technology.
- Lead product candidate (Entolimod) in advanced development.
- Potential for both radiation countermeasure and oncology applications.
- Experienced management team.
Was sind die Schwaechen von CBLI?
- Significant financial losses and negative profit margin.
- Dependence on successful clinical trial outcomes.
- High regulatory hurdles and approval risks.
- Limited commercialization experience.
Welche Chancen hat CBLI?
- Government contracts for radiation countermeasures.
- Partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Accelerated approval pathways for orphan drug designations.
Welchen Risiken ist CBLI ausgesetzt?
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Regulatory setbacks.
- Inability to secure additional funding.
Wer sind die Wettbewerber von CBLI?
- Catalyst Biosciences, Inc. — Focuses on hemostasis-related therapies. — (CATB)
- Celularity Inc. — Develops cellular medicines from the postpartum placenta. — (CELU)
- CARGO Therapeutics, Inc. — Focuses on cancer therapies. — (CRGX)
- IN8bio, Inc. — Develops gamma-delta T cell therapies for cancer. — (INXB)
- MACK — Unknown — (MACK)
Key Metrics
- Volume: 0
- MoonshotScore: 50/100
Company Profile
- CEO: Yakov Kogan
- Headquarters: Buffalo, US
- Employees: 18
- Founded: 2006
AI Insight
Fragen & Antworten
What does Cytocom, Inc. do?
Cytocom, Inc. is a biopharmaceutical company that focuses on developing and commercializing novel immunotherapies and radiation countermeasures. The company's core technology platform is based on Toll-like immune receptor activators, which stimulate the immune system to fight diseases and mitigate the effects of radiation exposure. Their lead product candidate, Entolimod, is being developed for both radiation mitigation and oncology indications. Cytocom aims to address unmet medical needs in these areas through innovative drug development.
What do analysts say about CBLI stock?
AI analysis is pending for CBLI. However, generally, biotechnology stocks are evaluated based on the potential of their drug pipeline, clinical trial results, and regulatory milestones. Key valuation metrics include market capitalization, cash burn rate, and potential revenue from future product sales. Growth considerations involve the successful development and commercialization of drug candidates, as well as the company's ability to secure funding and partnerships.
What are the main risks for CBLI?
The main risks for Cytocom, Inc. include clinical trial failures, regulatory setbacks, competition from established pharmaceutical companies, and the inability to secure additional funding. Clinical trial failures can significantly impact the company's valuation and future prospects. Regulatory setbacks can delay or prevent the approval of drug candidates. Competition from larger companies with greater resources poses a significant challenge. The company's financial losses and negative profit margin highlight the importance of securing additional funding to sustain operations.
What revenue streams does Cytocom, Inc. have in healthcare?
Currently, Cytocom, Inc. does not have established revenue streams as it is in the development stage. Potential future revenue streams include government contracts for radiation countermeasures, licensing agreements with pharmaceutical companies, and product sales upon regulatory approval of Entolimod or other drug candidates. The success of these revenue streams depends on the successful development, approval, and commercialization of their products.
How does Cytocom, Inc. navigate regulatory approval processes?
Cytocom, Inc. navigates regulatory approval processes by conducting preclinical and clinical trials to demonstrate the safety and efficacy of its drug candidates. The company works closely with regulatory agencies like the FDA to ensure compliance with regulatory requirements. They also seek accelerated approval pathways, such as orphan drug designations, for specific indications. Their regulatory strategy involves submitting comprehensive data packages and engaging in ongoing communication with regulatory agencies.
Is CBLI a good investment right now?
Use the AI score and analyst targets on this page to evaluate Cytocom, Inc. (CBLI). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.
What is the MoonshotScore for CBLI?
The MoonshotScore is a proprietary 0-100 AI rating that evaluates Cytocom, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.
Where can I find CBLI financial statements?
Cytocom, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.